Wockhardt Ltd (NSE: WOCKPHARMA, BSE: 532300) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹29,276 Cr, it ranks #274 by market cap among the 6,189 Indian listed companies on FinBizNet, and #14 of 86 in Medicinal Chemicals and Botanical Products. At ₹1,801.70 (as of 26 Oct 2026), the share price is 25.6% below its 52-week high of ₹2,422.30 and 65.8% above its 52-week low of ₹1,086.70. The share price is up 32.8% over one year and down 2.6% over three months.
| Current Price | ₹1,801.70 |
|---|---|
| Market Cap | ₹29,276 Cr |
| NSE Symbol | WOCKPHARMA |
| BSE Code | 532300 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 137.5 |
| Return on Equity | 4.00% |
| Return on Assets | 3.67% |
| 52-Week Range | ₹1,086.70 – ₹2,422.30 |
| 1-Year Price Change | +32.8% |
| 3-Month Price Change | -2.6% |
| Beta (1Y) | 1.03 |
| Dividend Yield | 0.00% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.wockhardt.com |
| Revenue | ₹929 Cr |
|---|---|
| Net Profit | ₹107 Cr |
| Net Margin | 11.5% |
| EPS (Basic) | ₹6.55 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatiti
1. Others-This segment manufactures and markets active pharmaceutical ingredients, formulations, bio-similars, and vaccines. 2. Pharmaceutical Business-This segment comprises marketing of biopesticides and agro products.
1. Pharmaceutical Business-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,19,404 Cr | 36.6 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,658 Cr | 22.5 | 18.32% | ₹8,017 Cr | +14.7% |
| Cipla Limited | ₹1,08,090 Cr | 27.9 | 11.74% | ₹7,119 Cr | -14.7% |
| Laurus Labs Ltd | ₹1,06,442 Cr | 119.8 | 17.74% | ₹2,026 Cr | +125.7% |
| Dr.Reddys Lab | ₹1,02,010 Cr | 23.8 | 11.52% | ₹8,698 Cr | -0.9% |
| Mankind Pharma | ₹91,379 Cr | 47.8 | 12.45% | ₹4,031 Cr | -9.9% |
| Aurobindo Pharma Ltd. | ₹90,432 Cr | 26 | 9.93% | ₹9,150 Cr | +41.7% |
| Lupin Ltd | ₹88,018 Cr | 16.5 | 26.91% | ₹8,277 Cr | -1.1% |
| Wockhardt Ltd | ₹29,276 Cr | 137.5 | 4.00% | ₹929 Cr | +32.8% |
Listed by market capitalisation. Ratios are shown for context only.
Wockhardt Ltd is trading at ₹1,801.70, with a market capitalisation of ₹29,276 Cr.
Wockhardt Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Wockhardt Ltd has a P/E of 137.5 and a return on equity of 4.00%.
Wockhardt Ltd is listed on the NSE under the symbol WOCKPHARMA and on the BSE under the scrip code 532300.
Wockhardt Ltd's share price is up 32.8% over one year and down 2.6% over three months. Its 52-week range is ₹1,086.70 to ₹2,422.30.
In Q1 FY27, Wockhardt Ltd reported revenue of ₹929 Cr and net profit of ₹107 Cr, with basic EPS of ₹6.55 (consolidated, parsed from the company's exchange filing).
Data as of 26 Oct 2026. Descriptive market data only — not investment advice.